RECENT POSTS
- Your First Move For Wednesday November 10th
- Web Extra: The Best Trades In Tech
- Pops & Drops: UPS, Electronic Arts...
- Take Your Position: Retail Earnings
- The Return of Dividend Investing?
- Should You Believe in this Rally?
- Trading in this Technicals-Driven Market
- HALFTIME REPORT: How to Trade Senator Dodd's Financial Reforms
FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our "Question of the Day" right now.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
In late breaking news CNBC’s Pharma reporter Mike Huckman reveals that Pfizer [PFE
Loading...
()
] is discontinuing a late-stage study of its cancer drug Sutent as an initial treatment for colon cancer because the drug is not proving effective enough.
Sutent is approved for advanced kidney cancer and gastrointestinal cancer.
The clinical trial compared the drug in combination with a type of chemotherapy against patients taking the chemotherapy alone. The Sutent combination was no more effective at improving the time a patient survives without the cancer progressing.
In addition, Huckman explains that AMAG Pharmaceuticals [AMAG
Loading...
()
] said on Tuesday U.S. regulators have approved its injectable anemia medicine Feraheme and that it will be made available to patients by the second half of July, lifting shares of the company by 5 percent after hours.
AMAG said the U.S. Food and Drug Administration had approved the drug as an iron replacement therapy in adults with iron deficiency anemia that have chronic kidney disease.
What’s the trade?
It might be worth playing AMAG for a little bit of a ride, counsels Guy Adami.
I think the trade is long XBI [XBI
Loading...
()
], adds Joe Terranova.
- Your First Move For Wednesday November 10th
- Web Extra: The Best Trades In Tech
- Pops & Drops: UPS, Electronic Arts...
- Take Your Position: Retail Earnings
- The Return of Dividend Investing?
- Should You Believe in this Rally?
- Trading in this Technicals-Driven Market
- HALFTIME REPORT: How to Trade Senator Dodd's Financial Reforms
- Your First Move For Tuesday November 9th
- Web Extra: The Dow's Only Loser
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap! If you'd prefer to make a comment but not have it published on our website send your e-mail to .
*CNBC.com and The Associated Press
Data is a real-time snapshot *Data is delayed at least 15 minutes